Targeting the oncogenic Met receptor by antibodies and gene therapy

The receptor for hepatocyte growth factor (HGF), a tyrosine kinase encoded by the Met oncogene, has a crucial role in cancer growth, invasion and metastasis. It is a validated therapeutic target for 'personalized' treatment of a number of malignancies. Therapeutic tools prompting selective...

Full description

Saved in:
Bibliographic Details
Published in:Oncogene 2015-04, Vol.34 (15), p.1883-1889
Main Authors: Vigna, E, Comoglio, P M
Format: Article
Language:English
Subjects:
Animals
Antibodies
Antibodies - administration & dosage
Antibodies - immunology
c-Met protein
Cancer
Care and treatment
Gene therapy
Genetic aspects
Genetic Therapy - methods
Health aspects
Hepatocyte growth factor
Humans
Kinases
Metastases
Metastasis
Molecular Targeted Therapy
Neoplasms - enzymology
Neoplasms - genetics
Neoplasms - immunology
Neoplasms - therapy
Physiological aspects
Polyclonal antibodies
Protein tyrosine kinase
Proto-Oncogene Proteins c-met - genetics
Proto-Oncogene Proteins c-met - immunology
Therapeutic applications
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The receptor for hepatocyte growth factor (HGF), a tyrosine kinase encoded by the Met oncogene, has a crucial role in cancer growth, invasion and metastasis. It is a validated therapeutic target for 'personalized' treatment of a number of malignancies. Therapeutic tools prompting selective, robust and highly effective Met inhibition potentially represent a major step in the battle against cancer. Antibodies targeting either Met or its ligand HGF, although challenging, demonstrate to be endowed with promising features. Here we briefly review and discuss the state of the art in the field.
ISSN:0950-9232
1476-5594
DOI:10.1038/onc.2014.142